{"references": ["K. Ley, C. Laudanna, M.I. Cybulsky and S. Nourshargh. \"Getting to the site of inflammation: the leukocyte adhesion cascade updated.\" Nature Reviews Immunology, vol. 7, pp. 678-689, September 2007.", "D. E.Staunton, M. L. Dustin and T.A. Springer. \"Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1.\" Nature, pp. 339: 61-64. 1989.", "A. R.de Fougerolles, S. A. Stacker, R. Schwarting and T. A. Springer \"Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1.\" Journal of Experiment Medicine, vol. 174, pp. 253-267, 1991.", "T. G. Diacovo, A. R.de Fougerolles, D. F. Bainton and T. A. Springer. \"A functional integrin ligand on the surface of platelets: inter-cellular adhesion molecule-2.\" Journal of Clinical Investigation, vol. 94, pp.1243-1251, 1994.", "N. Gerwin, J. A. Gonzalo, C. Lloyd, A. J. Coyle, Y. Reiss, N. Banu, B. Wang, H. Xu, H. Avraham, B. Engelhardt, T. A. Springer, J. C. Gutierrez-Ramos. \"Prolonged eosinophil accumulation in allergic lung interstitium of ICAM-2 deficient mice results in extended hyper-responsiveness.\" Immunity, vol.10, pp. 9-19, 1999.", "J. T. Pai and E. Ruoslahta. \"Identification of endothelial genes up-regulated in vivo.\" Gene, vol.347, pp. 21-33, 2005.", "O. D. Perez, S. Kinoshita, Y. Hitoshi, D. G. Payan, T. Kitamura, G. P. Nolan and J. B. Lorens. \"Activation of the PKB/AKT pathway by ICAM-2.\" Immunity, vol. 16 issue 1, pp. 51-65, 2002.", "L. Zhiyong, G. Ben and D.L. Richard. \"Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human (gamma)(delta)-T cells: Implications in the design of (gamma)(delta)-T-cell-based immunotherapies for pancreatic cancer.\" Journal of Gastroenterology & Hepatology, vol. 24 issue 5, pp. 900-911, 2009.", "N. Hiraoka, R. Yamazaki-Itoh, Y. Ino, Y. Mizuguchi, T. Yamada, S. Hirohashi and Y. Kanai. \"CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis.\" Gastroenterology, vol. 140, pp. 310-321, 2011.\n[10]\tI. Melero, I. Gabari, A. L. Corb\u0131\u00b4, M. Relloso, G. Mazzolini, V. Schmitz, M. Rodriguez-Calvillo, I. Tirapu, E. Camafeita, J. P. Albar, and J. Prieto. \"An Anti-ICAM-2 (CD102) Monoclonal Antibody Induces Immune-mediated Regressions of Transplanted ICAM-2-negative Colon Carcinomas.\" Cancer Research, vol. 62, pp. 3167\u20133174, June 1, 2002.\n[11]\tP. Galea, C. Vermot-Desroches, C. Le Contel, J. Wijdenes and J. C. Chermann. \"Circulating cell adhesion molecules in HIV1-infected patients as indicator markers for AIDS progression.\" Research Immunology, vol. 148, pp. 109-117, 1997.\n[12]\tK. J. Yoon, D. A. Phelps, R. A. Bush, J. S. Remack, C. A. Billups and J. D. Khoury. \"ICAM-2 Expression Mediates a Membrane-Actin Link, Confers a Nonmetastatic Phenotype and Reflects Favorable Tumor Stage or Histology in Neuroblastoma.\" PLoS ONE, vol. 3 issue 11, e3629 November 2008.\n[13]\tH. Tanaka, M. Yashiro, T. Sunami, Y. Sakate, K. Kosaka, and K. Hirakawa. \"ICAM-2 Gene Therapy for Peritoneal Dissemination of Scirrhous Gastric Carcinoma.\" Clinical Cancer Research, vol. 10, pp. 4885\u20134892, July 15, 2004.\n[14]\tK. J. Yoon and M. K. Danks. \"Review : Cell adhesion molecules as targets for therapy of neuroblastoma.\" Cancer Biology & Therapy, vol. 8 issue 4, pp. 306-311, 15 February 2009.\n[15]\tJ. Sambrook, E.F. Frisch, and, T. Maniatis, \"Molecular Cloning, A Laboratory Manual\", Cold Spring Harbor: Cold Spring Harbor Laboratory Press.,1989.\n[16]\tA. R. de Fougerolles, S. A. Stacker, R. Schwarting and T. A. Springer. \"Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1.\" Journal of Experimental Medicine, vol. 174, pp. 253-267, July 1991.\n[17]\tH. Xu, J. K. Bickford, E. Luther, C. Carpenito, F. Takei, T.A. Springer. \"Characterization of murine intercellular adhesion molecule-2.\" Journal of Immunology, vol. 156 issue 12, pp. 4909-4914. June 15, 1996.\n[18]\tJ. M. Casasnovas, T. A. Springer, J. H. Liu, S. C. Harrison and J. H. Wang. \"Crystal structure of ICAM-2 reveals a distinctive integrin recognition surface.\" Nature, vol. 387 issue 6630, pp. 312-315, May 15, 1997.\n[19]\tJ. W. Godwina, A. J. F. d'Apicea and P. J. Cowana. \"Characterization of Pig Intercellular Adhesion Molecule-2 and its Interaction with Human LFA-1.\" American Journal of Transplantation, vol. 4, pp. 515\u2013525, 2004."]}

ICAM-2 (intercellular adhesion molecule 2) or CD102 (Cluster of Differentiation 102) is type I transmembrane glycoproteins, composing 2-9 immunoglobulin-like C2-type domains. ICAM-2 plays the particular role in immune response and cell surveillance. It is concerned in innate and specific immunity, cell survival signal, apoptosis, and anticancer. EST clone of ICAM-2, from P. gigas blood cell EST libraries, showed high identity to human ICAM-2 (92%) with conserve region of ICAM N-terminal domain and part of Ig superfamily. Gene and protein of ICAM-2 has been founded in mammals. This is the first report of ICAM-2 in fish